and decreased spectral beta power has been the most commonly reported (Jelic et al., 2000; Poil et al., 2013; Musaeus et al., 2018b). This study suggests that gamma/theta CFC may serve as a marker of progression but has some limitations for clinical application due to low signal-to-noise ratio in the gamma band and the possible necessity to conduct the EEG during a task. More studies are needed to understand the applicability of gamma/theta CFC, which may, however, be beneficial in research on the pathophysiology of progressive neurodegenerative disorders vs. non-progressive conditions and potentially also in clinical trials.
